Because alteration of TGF-β signaling and its pharmacological modulation is critical in the pathogenesis of the vascular disease of MFS [Holm et al., 2011], we hypothesized that this altered TGF-β signaling may also affect the skeleton of MFS patients. The gene discussed is TGFB1; the disease is Marfan syndrome.